COLD SPRING HARBOR LABORATORY Patent applications |
Patent application number | Title | Published |
20150353929 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING - Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. | 12-10-2015 |
20150284732 | MUTATIONS IN SOLANACEAE PLANTS THAT MODULATE SHOOT ARCHITECTURE AND ENHANCE YIELD-RELATED PHENOTYPES - Provided herein are genetically-altered Solanaceae plants, compositions related to the Solanaceae plants, and methods of making the Solanaceae plants. | 10-08-2015 |
20150275211 | ANTISENSE COMPOUNDS AND USES THEREOF - The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript. Certain such compounds are useful for hybridizing to a pyruvate kinase M transcript, including but not limited to a pyruvate kinase M transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the pyruvate kinase M transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with cancer. | 10-01-2015 |
20150197749 | Novel Structurally Designed shRNAs - Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules. | 07-16-2015 |
20150047071 | NUCLEOTIDE SEQUENCES ENCODING FASCIATED EAR3 (FEA3) AND METHODS OF USE THEREOF - Methods and compositions for modulating shoot apical meristem size are provided. Methods are provided for modulating the expression of fea3 sequence in a host plant or plant cell to modulate agronomic characteristics such as altered size and number of organs, including plant seeds. | 02-12-2015 |
20150025231 | COMPOSITIONS AND METHODS FOR MODULATION OF IKBKAP SPLICING - The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia. | 01-22-2015 |
20140357558 | COMPOSITIONS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY - Disclosed herein are compounds, compositions and methods for treatment of diseases and disorders, including spinal muscular atrophy. | 12-04-2014 |
20140298496 | PHENOCOPY MODEL OF DISEASE - Methods and compositions for generating nonhuman disease models through splicing modulation. | 10-02-2014 |
20140297199 | DRUG SCREENING METHOD AND USES THEREOF - Described herein are methods of screening drugs in a non-human animal using high resolution technology leading to generation of pharmacomaps. Further described herein are methods of predicting the therapeutic benefit and/or toxicity of drug candidate compounds. In specific embodiments, provided herein are methods of predicting the clinical effects of a test drug based on comparison of the pharmacomap of the test drug to the pharmacomap of one or more reference drugs with known clinical outcomes. | 10-02-2014 |
20140283156 | TRANS-SPLICING RIBOZYMES AND SILENT RECOMBINASES - The present invention provides a trans-splicing ribozyme comprising i) a targeting nucleotide sequence that is complementary to a target nucleotide sequence within a mRNA that is expressed in a cell; contiguous with ii) a catalytic RNA sequence; contiguous with iii) a donor transcript, which donor transcript comprises at least a nucleotide sequence that encodes a trans-activator, wherein when the trans-splicing ribozyme is expressed in a cell, the catalytic RNA sequence cleaves the mRNA and ligates the donor transcript to the mRNA to generate a spliced mRNA which comprises the donor transcript, such that the donor transcript is translated as part of the spliced mRNA in the cell, as well as methods of using the trans-splicing ribozyme. The present invention also provides variants of Cre and other recombinases, as well as method of using the variants. | 09-18-2014 |
20140272988 | TRANS-SPLICING TRANSCRIPTOME PROFILING - The present invention provides a method of identifying mRNA transcripts in the transcriptome of a cell comprising i) delivering into the cell a donor expression vector comprising nucleotides in a sequence encoding a trans-splicing barcode cassette, wherein the trans-splicing barcode cassette comprises a) a first portion, the nucleotide sequence of which encodes an intron comprising as part of its 3′ end, or followed at its 3′ end by a splice-site nucleotide sequence; followed at its 3′ end by, b) a second portion, the nucleotide sequence of which encodes a barcode polynucleotide; followed at its 3′ end by c) a third portion, which encodes a nucleotide identification element sequence, ii) exposing the cell to conditions such that the cell produces multiple copies of the trans-splicing barcode cassette encoded by the donor expression vector, which multiple copies of the trans-splicing barcode cassette each splice the barcode polynucleotide onto a mRNA transcript of the cell, thereby forming multiple mRNA transcripts of the cell, each spliced to the barcode polynucleotide; and iii) identifying the multiple mRNA transcripts that are spliced to the barcode polynucleotides, thereby identifying mRNA transcripts in the transcriptome of the cell. | 09-18-2014 |
20140200244 | PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS - Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): | 07-17-2014 |
20140143898 | MUTATIONS IN SOLANACEAE PLANTS THAT MODULATE SHOOT ARCHITECTURE AND ENHANCE YIELD-RELATED PHENOTYPES - Provided herein are genetically-altered Solanaceae plants, compositions related to the Solanaceae plants, and methods of making the Solanaceae plants. | 05-22-2014 |
20140113952 | TRANSPOSABLE ELEMENTS, TDP-43, AND NEURODEGENERATIVE DISORDERS - A method that includes measuring the expression level of at least one transposon in a biological sample from a subject; and determining whether the measured transposon expression exceeds a predetermined level, and if so, administering to the subject a transposon inhibitor in an amount effective to reduce the expression level of a transposon. | 04-24-2014 |
20140025307 | DETERMINING A PROBABILISTIC DIAGNOSIS OF CANCER BY ANALYSIS OF GENOMIC COPY NUMBER VARIATIONS - The present invention provides methods and compositions related to genomic profiling, and in particular, to assigning probabilistic measure of clinical outcome for a patient having a disease or a tumor using segmented genomic profiles such as those produced by representational oligonucleotide microarray analysis (ROMA). | 01-23-2014 |
20140011862 | Compositions and Methods for Treating Leukemia - The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject. | 01-09-2014 |
20130289092 | COMPOUNDS AND METHODS FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS - Provided herein are antisense compounds and methods for recruiting one or more non-cleaving protein to a target nucleic acid in a cell. In certain instances such recruitment of a non-cleaving protein alters the function or activity of the target nucleic acid. In certain such instances, the target nucleic acid a pre-mRNA and the recruitment of the non-cleaving protein results in a change in splicing of the pre-mRNA. | 10-31-2013 |
20130276158 | METHODS AND COMPOSITIONS FOR RNA INTERFERENCE - The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene). | 10-17-2013 |
20130219553 | NUCLEOTIDE SEQUENCES ENCODING RAMOSA3 AND SISTER OF RAMOSA3 AND METHODS OF USE FOR SAME - The invention relates to the isolation and characterization of a maize gene, RAMOSA3 (RA3), responsible for meristem development and inflorescence development including branching. The gene, gene product, and regulatory regions may be used to manipulate branching, meristem growth, inflorescence development and arrangement, and ultimately to improve yield of plants. The invention includes the gene and protein product as well as the use of the same for temporal and spatial expression in transgenic plants to alter plant morphology and affect yield in plants. The invention also includes the gene and protein product for SISTER OF RAMOSA3 (SRA). | 08-22-2013 |
20130196877 | IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS - The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system. | 08-01-2013 |
20130179999 | NOVEL STRUCTURALLY DESIGNED shRNAs - Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules. | 07-11-2013 |
20130164721 | AUGMENTED COGNITIVE TRAINING - The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents. | 06-27-2013 |
20130097718 | CHD5 IS A NOVEL TUMOR SUPPRESSOR GENE - The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof. Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening. | 04-18-2013 |
20130074200 | INBRED C57BL/6 ES CELLS WITH HIGH DEVELOPMENTAL CAPACITY - Described herein are inbred B6 ES cell lines that exhibit high developmental capacities and have a number of advantages over ES cell lines already available. First, they can be used for gene targeting and have a high percentage of germline transmission when injected into diploid host blastocysts (˜50-80%). Second, these ES cell lines can successfully be used to generate live pups by tetraploid blastocyst complementation, producing a high percentage (15-20%) of mice that are entirely inbred B6 ES cell derived. Third, these ES cells lines can be used to rapidly generate mice that are homozygous for a gene of interest. These advantages indicate that the inbred B6 ES cells provided here facilitate the rapid generation of inbred B6 mouse models in a cost-effective and efficient manner. | 03-21-2013 |
20130029366 | PTP1B INHIBITORS - Described herein are agents, including antibodies, antibody fragments, polypeptides and organic small molecules, that bind reversibly inactive PTP1B (designated herein in the alternative as PTP1B-SN or PTP1B-OX) and stabilize it (stabilize PTP1B-OX) in such a manner that they inhibit reactivation of reversibly oxidized, inactive PTP1B by reduction (by reducing agent) and have no substantial direct inhibitory effect on phosphatase activity/PTP1B activity (for example, as detectable in assays in vitro). | 01-31-2013 |
20120309017 | PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers. | 12-06-2012 |
20120294804 | PHENYLETHANOLAMINE-BASED NMDA RECEPTOR ANTAGONISTS - Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment, e.g., of Formula (I): | 11-22-2012 |
20120192299 | INBRED C57BL/6 ES CELLS WITH HIGH DEVELOPMENTAL CAPACITY - Described herein are inbred B6 ES cell lines that exhibit high developmental capacities and have a number of advantages over ES cell lines already available. First, they can be used for gene targeting and have a high percentage of germline transmission when injected into diploid host blastocysts (˜50-80%). Second, these ES cell lines can successfully be used to generate live pups by tetraploid blastocyst complementation, producing a high percentage (15-20%) of mice that are entirely inbred B6 ES cell derived. Third, these ES cells lines can be used to rapidly generate mice that are homozygous for a gene of interest. These advantages indicate that the inbred B6 ES cells provided here facilitate the rapid generation of inbred B6 mouse models in a cost-effective and efficient manner. | 07-26-2012 |
20120164673 | PTP1B INHIBITORS - Described herein are agents, including antibodies, antibody fragments, polypeptides and organic small molecules, that bind reversibly inactive PTP1B (designated herein in the alternative as PTP1B-SN or PTP1B-OX) and stabilize it (stabilize PTP1B-OX) in such a manner that they inhibit reactivation of reversibly oxidized, inactive PTP1B by reduction (by reducing agent) and have no substantial direct inhibitory effect on phosphatase activity/PTP1B activity (for example, as detectable in assays in vitro). | 06-28-2012 |
20120084872 | METHODS FOR PRODUCING MICRORNAS - The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene. | 04-05-2012 |
20110224103 | METHOD FOR DESIGN OF AN OLIGINUCLEOTIDE ARRAY - A method is provided allowing for automatic selection of enzymes to be used in protocols such as methylation profiling, chip-on-chip, and comparative genomic hybridization experiments. The method may also maximize the space on a micro array for a given experiment. This means that the results from the micro array are improved. The method also improves zero-in and focus of significant patterns on a micro array. This enhances the ability to distinguish two separate classes of samples, e.g. tumour vs. normal, aggressive vs. non-aggressive, male vs. female, etc. Furthermore, a computer readable medium and a device are also provided. | 09-15-2011 |
20110207625 | PIRNA AND USES RELATED THERETO - The invention relates to small single stranded RNAs and analogs thereof (collectively “piRNA” herein), compositions comprising such piRNAs, and their uses in regulating target gene expression or as markers for certain disease states. | 08-25-2011 |
20110162108 | NUCLEOTIDE SEQUENCES ENCODING RAMOSA3 AND SISTER OF RAMOSA3 AND METHODS OF USE FOR SAME - The invention relates to the isolation and characterization of a maize gene, RAMOSA3 (RA3), responsible for meristem development and inflorescence development including branching. The gene, gene product, and regulatory regions may be used to manipulate branching, meristem growth, inflorescence development and arrangement, and ultimately to improve yield of plants. The invention includes the gene and protein product as well as the use of the same for temporal and spatial expression in transgenic plants to alter plant morphology and affect yield in plants. The invention also includes the gene and protein product for SISTER OF RAMOSA3 (SRA). | 06-30-2011 |
20110105583 | METHODS OF USING MIR34 AS A BIOMARKER FOR TP53 FUNCTIONAL STATUS - In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer. | 05-05-2011 |
20110055941 | Chd5 is a novel tumor suppressor gene - The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening. | 03-03-2011 |
20110035814 | COOPERATING ONCOGENES IN CANCER - This invention provides methods of diagnosis, drug screening, and treatment based on the discovery that cIAP1 and Yap are co-amplified oncogenes that cooperate to contribute to oncogenesis and tumor maintenance. | 02-10-2011 |
20110015093 | HIGH THROUGHPUT METHODS FOR FUNCTIONALLY DETERMINING RNA INTERFERENCE EFFICIENCY - Provided is a single construct combining a sequence encoding an RNAi molecule, a sequence encoding a reporter, and a target sequence specific for the RNAi molecule. The construct can be used to determine the potency of the encoded RNAi molecule in a direct and unbiased way. These results can be used to inform the design of potent RNAi molecules of various types and can be extended to several other applications, including: (1) generation of tiled libraries comprising every possible RNAi molecule-encoding sequence for a given gene target; (2) large-scale parallel validation of RNAi molecules targeting many genes to generate validated RNAi molecule-encoding libraries; (3) experimental comparison of design algorithms and strategies; and (4) investigation of RNAi biology in target site mutagenesis assays by screening pools containing single nucleotide changes in target sites and/or in the RNAi molecule to identify the most relevant sequence characteristics of potent RNAi-target site predictions. | 01-20-2011 |
20100273660 | ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS - In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal. | 10-28-2010 |
20100186097 | CELL-BASED RNA INTERFERENCE AND RELATED METHODS AND COMPOSITIONS - The invention provides, among other things, methods for performing RNA interference in stem cells and methods for using the stem cells in vivo. | 07-22-2010 |
20100160172 | METHODS AND SYSTEMS OF DNA SEQUENCING - Methods and systems of DNA sequencing that compensate for sources of noise in next-generation DNA sequencers are described. | 06-24-2010 |
20100075365 | PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers. | 03-25-2010 |
20090286242 | MicroRNA Expression Profiling and Uses Thereof - Provided are methods and reagents for obtaining microRNA expression profiles in selected cell populations or sub-populations, such as stem cell or progenitor cell populations, and using such microRNA expression profiles for cell characterization, isolation/purification, and/or reinforcement of cell fate specification, both in research & development, and in therapeutic applications. Also provided are methods of identifying and isolating mammary progenitor cells using miRNA sensor constructs. | 11-19-2009 |
20090247860 | SPECTRAL BIOMARKER AND ALGORITHM FOR THE IDENTIFICATION AND DETECTION OF NEURAL STEM AND PROGENITOR CELLS AND THEIR USE IN STUDYING MAMMALIAN BRAINS - The disclosure provides a biomarker and algorithm for identifying and detecting neural stem and progenitor cells and their use in studying mammalian brains. The disclosure further provides magnetic resonance spectroscopy methods and an image enhancing algorithm for the study of the proliferation of these cells and the associated neurogenesis in the live mammalian brain. | 10-01-2009 |
20090193531 | Methods and compositions for RNA Interference - The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene). | 07-30-2009 |
20090186839 | Model for studying the role of genes in chemoresistance - The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth transformed cells and thereby reduce hyperproliferative conditions, such as cancer progression, in select patient populations having particular tumor genotypes. The invention also provides methods which target translation initiation controls in growth-transformed cells, such as tumor subtypes with altered expression of a gene activity, including the human akt, bcl-2, eIF4E, eIF4A or PTEN activities, to restore drug sensitivity in vivo in a genotype selective manner. In one aspect, the inhibitors of translation initiation of the invention are rocaglates, i.e., cyclopenta[b]benzofurons, which increases chemosensitivity or diminishes or reverses chemoresistance either alone or in combination, additively or synergistically, with other agents that alter growth or death. Preferably, the rocaglate is silvestrol, which is used alone or in combination with doxorubicin to reverses chemoresistance in PTEN-deficient lymphomas or eIF4E-over-expressing lymphomas and to promote cancer remission. | 07-23-2009 |
20090162848 | Noxin, a novel stress-induced gene involved in cell cycle and apoptosis - The invention provides for novel noxin polypeptides and nucleic acids from humans, rats, and mice and to related compositions and uses. The invention also provides for the creation of non-human, transgenic mammals which have, incorporated in their genome, DNA that includes a sequence of a mammalian noxin gene that does not produce noxin polypeptides, i.e. a noxin knockout mouse. | 06-25-2009 |
20090082298 | Methods for producing microRNAs - The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene. | 03-26-2009 |
20090029872 | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof - This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal. | 01-29-2009 |
20080300145 | In vivo high throughput selection of RNAi probes - In mammalian systems, RNA interference (RNAi)-based suppression of target gene expression may be activated by delivery of RNAi probes such as double stranded small interfering RNA (siRNA) molecules or short hairpin RNAs (shRNAs), where the RNAi probe sequence is homologous to the target-gene. A reliable and quantitative method is provided for the rapid and efficient identification of RNAi probes that are most effective in providing RNAi-mediated suppression of target gene expression. This method may be used for high-throughput screens to identify effective RNAi probes. | 12-04-2008 |
20080242622 | Identification of genetic alterations that modulate drug sensitivity in cancer treatments - This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy. | 10-02-2008 |
20080226553 | Cell-Based Rna Interference and Related Methods and Compositions - This invention provides, among other things, methods for performing RNA interference in stem cells and methods for using stem cells in vivo. | 09-18-2008 |